Abstract
The use of bacterial spores in probiotics over viable loads of bacteria has many advantages, including the durability of spores, which allows spore-based probiotics to effectively traverse the various biochemical barriers present in the gastrointestinal tract. However, the majority of spore-based probiotics developed currently aim to treat adults, and there is a litany of differences between the adult and infant intestinal systems, including the immaturity and low microbial species diversity observed within the intestines of infants. These differences are only further exacerbated in premature infants with necrotizing enterocolitis (NEC) and indicates that what may be appropriate for an adult or even a healthy full-term infant may not be suited for an unhealthy premature infant. Complications from using spore-based probiotics for premature infants with NEC may involve the spores remaining dormant and adhering to the intestinal epithelia, the out-competing of commensal bacteria by spores, and most importantly the innate antibiotic resistance of spores. Also, the ability of Bacillus subtilis to produce spores under duress may result in less B. subtilis perishing within the intestines and releasing membrane branched-chain fatty acids. The isolate B. subtilis BG01-4TM is a proprietary strain developed by Vernx Biotechnology through accumulating mutations within the BG01-4TM genome in a serial batch culture. Strain BG01-4TM was provided as a non-spore-forming B. subtilis , but a positive sporulation status for BG01-4TM was confirmed through in vitro testing and suggested that selection for the sporulation defective genes could occur within an environment that would select against sporulation. The durability of key sporulation genes was ratified in this study, as the ability of BG01-4TM to produce spores was not eliminated by the attempts to select against sporulation genes in BG01-4TM by the epigenetic factors of high glucose and low pH. However, a variation in the genes in isolate BG01-4-8 involved in the regulation of sporulation is believed to have occurred during the mutation selection from the parent strain BG01-4TM. An alteration in selected sporulation regulation genes is expected to have occurred from BG01-4TM to BG01-4-8, with BG01-4-8 producing spores within 24 h, ~48 h quicker than BG01-4TM.
Keywords: necrotizing enterocolitis, sporulation, Bacillus subtilis, mutation accumulation, serial batch culture, mutation selection
Introduction
The development of the intestinal disease necrotizing enterocolitis (NEC) is characterized by excessive inflammation within the intestines and has a pronounced rate of incidence in premature (<36 weeks) infants due to low intestinal microbial diversity [1–3]. During the first weeks of life, the intestinal microbiota of a full-term infant is reminiscent of the maternal oral, placental and amniotic microbiomes as a result of the successful mother–infant microbial transfer in utero [4–6]. The mother–infant microbial conduit ensures that the full-term infant’s intestinal microbiome is colonized with a relative level of commensal bacteria, such as Bacteroides spp., Bifidobacterium spp. and Propionibacterium spp., which are seen to indirectly mediate intestinal health and allow the infant to develop a stable intestinal microbiome post-natally through the production of short-chain fatty acids (SCFAs) [7, 8]. Enumeration of the foetus intestines with branched chain fatty acids (BCFAs) occurs in utero via the foetus’ ingestion of vernix caseosa, and is a pivotal process involved in the mother–infant transfer of microbial communities due to many of the bacteria passed on from the mother to the infant requiring and utilizing BCFAs [1, 9–11]. As a result of a premature birth (<36 weeks), an infant does not ingest vernix caseosa in utero and consequently does not have the appropriate levels of BCFAs within the intestines to support the colonization of certain BCFA commensal bacteria [1, 12, 13]. As low levels of BCFAs are consumed by a premature infant (<36 weeks) in utero, the commensal BCFA bacteria transferred from the mother to the infant are unable to colonize a premature infant’s intestines, directly resulting in a significantly lower microbial diversity in the intestines of premature infants compared with full-term (40 weeks) infants [13–15]. Although a low species diversity is consistently seen in intestinal microbiomes of premature infants, longitudinal studies have seen increased incidences of NEC in premature infants whose intestinal microbiomes are dominated by Proteobacteria and Firmicutes and contained low levels of Actinobacteria [16, 17]. On the other hand, premature infants who did not develop NEC were observed with significantly higher levels of Actinobacteria , in particular Bifidobacterium spp. and Propionibacterium spp., within the intestinal microbiome than the preterm infants who did develop NEC [16, 18, 19]. The pathogenesis of NEC has been linked to the increased numbers of the opportunistic pathogens Clostridium spp. or Klebsiella spp., within the intestines of infants, as they are consistently recorded at elevated levels in the faeces of premature infants preceding NEC diagnosis [20–22]. Species of Clostridium , C. perfringens , C. difficile and C. butyricum , and Klebsiella , K. oxytoca and K. pneumoniae , are often isolated from the faecal samples of NEC-affected premature infants and have all been implicated in the pathogenesis of NEC due to enteral toxin production [23–26]. Opportunistic infections by Clostridium spp. or Klebsiella spp. occur in premature infants as the intestines of premature infants are not enriched with BCFAs in utero and are consequently not colonized with appropriate levels of BCFA bacteria, compared with full-term infants [25, 27]. The inability of various BCFA bacteria to colonize the premature infant intestines allows for the increased growth of the opportunistic pathogens Clostridium spp. and Klebsiella spp. As the lack of BCFA consumption by the foetus’ in utero results in the inability of premature infants to be effectively colonized by commensal BCFA bacteria post-natally, the use of prebiotic BCFAs or a probiotic with high levels of BCFAs could stimulate the colonization of commensal BCFA bacteria and potentially limit the pathogenesis of NEC [1, 12, 13].
As a result of the inadequate microbial colonization observed in infants with NEC, the form of probiotic must differ from the probiotics used to treat more stable and mature intestinal systems [28–31]. The microbial diversity present within the intestines of premature infants, in particular premature infants with NEC, has been observed to be considerably lower and more unstable than the intestinal microbiomes of healthy full-term infants [32–34]. There is also a large disparity between the number of full-term and pre-term infants who receive antimicrobial treatment post-natally, with the majority of premature infants undergoing antibiotic regimes compared to <10 % of full-term infants [32, 35]. The administration of antibiotics to premature infants has been linked to an increased rate of incidence of NEC, as the antibiotics intended to restrict the overgrowth of opportunistic pathogens within the intestines also kill susceptible commensal bacteria [36–40]. Antibiotics have been found to be unsuccessful in decreasing the levels of antibiotic-resistant bacteria implicated in the pathogenesis of NEC, such as Klebsiella spp., and spore-forming bacteria, such as Clostridium difficile , which produce antibiotic-resistant spores [41–43]. Despite evidence which indicates the association of NEC progression and antibiotic exposure post-natally, antibiotic regiments are still prescribed in conjunction with probiotic supplements when treating infants with NEC [40, 44–46]. The low species diversity seen in the intestines of premature infants with NEC, coupled with the antibiotic exposure post-natally, suggests that the use of a probiotic bacterium capable of developing spores for infants with NEC may result in an overgrowth of the spore-forming probiotic [32–34, 43, 45–48]. In the case of Bacillus subtilis , a common bacterial strain used in probiotics, various complications may arise from the introduction of B. subtilis spores into an NEC intestinal environment, including the spores remaining dormant and adhering to the intestinal epithelia, restricting the interaction between the intestinal epithelia and commensal bacteria [49–54]. From the high levels of BCFAs, B. subtilis is an ideal probiotic for the treatment of NEC in premature infants, but due to the resistance and ability of B. subtilis spores to adhere to the intestinal epithelia, it is expected that B. subtilis spores could survive antibiotic treatments and may remain dormant attached to the intestinal epithelium [52–56]. The issue of B. subtilis spores persisting in the intestines of infants with NEC is that B. subtilis may outcompete various commensal bacteria attempting to colonize the infant’s intestinal epithelium [48, 52–54]. Furthermore, the ability of B. subtilis to form spores under duress may not result in as much of an increase in intestinal BCFAs, as opposed to a viable load of B. subtilis that is incapable of producing spores [55–59]. The decreased release of BCFAs may be seen as B. subtilis vegetative cells initiate sporulation in response to stress, instead of perishing and releasing BCFAs into the intestinal environment after being lysed [58–61]. Although the durability and resistance qualities of bacterial spores has made them ideal candidates for probiotics, the idea that a B. subtilis isolate incapable of producing spores will perish within the stomach suggests that the subsequent lysing of B. subtilis will release BCFAs and increase intestinal BCFAs more than B. subtilis spores which would survive degradation [60–62].
The development of a mutant bacterium for commercial use in probiotics is subject to public scrutiny in regard to the manner in which the genetics of the bacterium are modified [63, 64]. Organisms with modified genomes are categorized by the protocol that was used to create the genetic mutation, being classified as either a genetically modified organism (GMO) or a non-genetically modified organism (non-GMO) [63, 64]. A GMO is created through the direct mutation of the genome via recombinant nucleic acid or genome editing techniques, whilst a non-GMO requires that the alteration to the genome has occurred naturally [65]. From the ability to manipulate the genome with regard to a specific biological process, the creation of GMOs is far more accurate than non-GMOs, but the use of GMOs commercially in probiotics raises issues due to the lack of public trust and understanding of such protocols used to develop GMOs [63–65]. As a result, the creation of genetically modified probiotics is seen to occur via non-GMO strategies, which involves the use of natural reproduction in combination with environmental factors to create genetically variant progeny [65–68].
In order to develop a non-GMO non-spore-forming B. subtilis isolate, a variation in genetic material pertaining to key sporulation processes must occur naturally [65–68]. The loss and gain of genetic material is common amongst all organisms from generation to generation but occurs at a much faster rate in bacteria due to increased generational times [69–71]. The fast generational times of bacteria allow for the acquirement of mutations by bacterial isolates in real time through the use of specific environmental factors that affect the transcription of genes [72–75]. Mutation accumulation experiments have the capacity to develop genetically variant bacteria, as mutations are acquired by bacterial isolates within the population during the protocol within the population [76–78]. Mutations in bacterial genomes can alter the structure of genomes and in some cases affect the overall expression of genes and consequently the isolate’s phenotype [79]. Variations in bacterial genomes can occur at the nucleotide level through the substitution, deletion or addition of nucleotides in the DNA, and can be neutral mutations, which confer no additional fitness in regard to the isolate’s survival, or mutations may occur within a gene that may impact the phenotype in a negative or positive manner [79]. However, alterations to the genome at the chromosomal level are seen to have far more adverse effects on the genetic and phenotypic expression of a bacterium than point mutations, as seen in chromosomal rearrangements, such as duplication and deletion events of certain coding regions [80, 81]. These chromosomal altering events can have a greater impact upon the genetic expression of a bacterial genome, as the amplification or removal of a coding region will directly result in the up- or downregulation of the gene products transcribed from those coding sequences [80, 81]. This rearrangement of chromosomes was previously believed to have occurred randomly by genetic drift, but recent work has indicated that positive selection from an environment can alter the order of genes and affect what genes are transcribed [82].
Although genetic transformation via mutation may underpin the process of natural selection, mutations that alter the phenotype do not always lead to beneficial traits [83]. Protocols which aim to modify specific characteristics of a bacterium, in particular for commercial probiotic use, may often contradict the natural action of selection, as knocking-out genes pertaining to key cellular processes, such as sporulation, antimicrobial resistance and toxin production, are of great interest to developers of novel probiotic strains. The past use of mutation accumulation techniques has been proven successful in creating genetic variation in B. subtilis isolates, resulting in the alteration of metabolic pathways [76, 84, 85]. The neutral accumulation of mutations has been previously observed to result in the loss of sporulation in B. subtilis isolates, with four of the five B. subtilis populations found to have become non-spore-forming due to mutational degradation [86].
As various studies have indicated the role a lack of glucose plays in initiating sporulation, it is perceivable that B. subtilis cultured on media with high levels of glucose would be unable to initiate sporulation in response to nutrient exhaustion [87–91]. If cultured continuously over multiple generations with high levels of environmental glucose, it can be hypothesized that an inability to activate sporulation means that genes involved in sporulation may be lost over generations [87–91]. Similar results could be expected for B. subtilis cultured at a low pH, which is seen to negatively impact the activity of sigH [92, 93]. The decreased activity of sigH would result in lower transcription of sigH-dependent sporulation genes, and subsequently genes transcribed by sigH may in turn become null genes and may be lost over generations [72, 92–94].
Study rationale
In this study, we sought to determine the sporulation capacity of the new probiotic strain B. subtilis BG01-4TM, a proprietary strain developed for Vernx Biotechnology. After confirming the sporulation capacity of BG01-4TM, the focus of this study was to further develop BG01-4TM as a non-spore-forming strain of B. subtilis . The key factors surrounding this project include the development of a sporulation null B. subtilis isolate, but there were pressing constraints on the methodology and protocols used to create the new isolate. The procedures used in this experiment ensure that any genetic variation incurred by BG01-4TM isolates occurred via natural processes and are indicative of epigenetic factors created by the modified media. The previous mutation accumulation protocol which produced BG01-4TM was a serial batch culture utilizing a chemically defined liquid medium, modified from media previously described in a study by Leitch and Collier [95]. The intent was to create a non-spore-forming B. subtilis by allowing isolates to accumulate mutations that may negatively impact sporulation. Whilst the mutation accumulation protocol which produced BG01-4TM was not successful in creating a non-spore-forming isolate, the genomic analysis of BG01-4TM and the wild-type BG01-WT determined that BG01-4TM had undergone a genetic duplication event, with the BG01-4TM genome and coding sequences (CDS) increasing by more than double the size from the parent strain BG01-WT (10490086 bp/10360 CDS; 4111688 bp/4300 CDS). The increase in genetic material was confirmed not to be due to contamination as taxonomic classification via Kraken and Krona of the BG01-4TM genome determined the increase in genetic material was in unclassified Bacillus spp. and B. subtilis genes, with various mutations in genes involved in sporulation observed (Figs S1 and S2; Tables S3, S4 and S10, available in the online version of this article) [96, 97].
Despite BG01-4TM being observed to produce spores, the non-sporulating phenotype had been observed in single colonies of BG01-4TM when streaked and grown for extended periods of time on the solid version of the chemically defined media, previously used to serially culture BG01-4TM from BG01-WT. The potential to produce a non-sporulating isolate from BG01-4TM was perceived by successive single-cell bottlenecks, as recent work saw the loss of genes within bacterial genomes that had recently experienced genetic duplication events, after the continuous culturing of single colonies into an environment that diminishes the requirement of the isolate to express those genes [82].
As a result, this study aimed to grow BG01-4TM in an environment with extremely high levels of glucose and low pH in order to ensure the inactivity of sporulation genes and select for mutations already present within BG01-4TM that may negatively impact sporulation. This work opposed common practices used to create genetically variant bacteria through the use of streak dilutions on solid medium, which was utilized to guarantee the growth of monoclonal colonies from single cells, in attempts to create a new non-sporulating BG01-4TM isolate. A monoclonal colony was required for the reinoculation in this study, as a genetic variance required to impair sporulation will occur through deleterious alleles, which may be lost in a larger bacterial population. The importance of isolating samples from single colonies throughout this mutation selection protocol is to ensure that the epigenetic constraints of low pH and high glucose have acted upon a single colony, in turn allowing the introduction of a single-cell bottleneck onto the corresponding plate. A recent study has demonstrated that increased levels of genetic drift and gene loss occur within bacterial genomes that have previously experienced genetic duplication events [82]. This work suggests that due to duplication in genetic material in BG01-4TM genes involved in sporulation are lost via the continuous single-cell bottlenecking on media of that would not allow sporulation to be initiated. Whilst the concepts in these experiments originated from the idea of natural selection, the aim opposes natural selection, as during this protocol we attempt to decrease the fitness of B. subtilis by creating a non-spore-forming B. subtilis isolate.
Moreover, issues may arise with maintaining both a low pH and high glucose external environment within large colonies of B. subtilis , as large colonies of B. subtilis have been observed to indirectly modify the pH and glucose levels in the external environment [98–100]. In a study by Dervaux et al. [98], it was demonstrated that over the course of the experiment (48 h) the pH of the media had increased from the initial reading of pH 7.5 to over pH 9 [98]. Their study indicated that the ability to modify external pH by B. subtilis was a result of the export of an alkaline product produced by B. subtilis during the formation of biofilms [98]. The Dervaux et al. study indicates that in a larger population pH may become more alkaline as the potential for a biofilm to be formed would be greater than in a single colony, if grown with adequate nutrients, surface area and lack of interspecies competition [101, 102]. In addition, the utilization of glucose would be far greater within large populations than in single colonies, as a larger population will need to have fermented more glucose to exhibit increased growth rates [103]. Unfortunately, the increased growth rate and higher glucose utilization would decrease environmental glucose and limit the epigenetic effects of high glucose against sporulation genes within a large population opposed to single colonies, which will also still be exposed to uncolonized media [100, 103, 104].
The creation of a non-GMO B. subtilis isolate that is unable to produce spores will have great potential within the probiotic market, in particular for consumers with a lower immunity or poor intestinal microbiome, where spores may become an issue within the intestinal environment. This study will also provide insight into the genetic variability that may affect sporulation in B. subtilis .
Methods
Serial batch culturing of BG01-4TM from BG01-WT
BG01-4TM is a proprietary strain developed for Vernx. BG01-4TM was developed through serial culturing of the wild-type strain B. subtilis BG01-WT, isolated from the gastrointestinal system of Apis mellifera (honey bee). The serial batch process occurred in a Sartorius glass autoclavable bioreactor for over 692 h to produce BG01-4TM, utilizing a modified chemically defined medium described in a study by Leitch and Collier [95] (their personal communication).
BG01-4TM and BG01-WT DNA extraction protocol
The BG01-4TM and BG01-WT isolates were streaked and grown on blood agar (Table S2) for 48 h at 37 °C. DNA was then extracted from BG01-4TM and BG01-WT, and then prepared with the Zymo Research fungal/bacterial DNA miniprep kit (Supplementary Information 1). The DNA was then further prepared using a QIAseq FX DNA Library Kit [24] (Supplementary Information 2) for next generation sequencing (NGS) on an Illumina Miseq sequencing machine.
Genome annotation protocol
The BG01-4TM and BG01-WT genomes were assembled with the A5 miseq pipeline, and the assembled genome was uploaded to a genome annotation server, Prokka (via https://usegalaxy.org.au), with default parameters and the input of the genus ( Bacillus ) and species names (subtilis) (Galaxy Version 1.14.6) (Supplementary Information 3). The BG01-4TM and BG01-WT genomes were analysed for genes involved in sporulation regulatory systems, including the sporulation delay operon (sdp) and the sporulation killing factor operon (skf) (Table S10).
Genome contamination protocol
To establish what genetic material has contributed to the increase in the genome size of BG01-4TM, both isolate genomes (BG01-4TM and BG01-WT) were run through the taxonomic classifier Kraken (via Galaxy Version 1.14.6), which produced independent Kraken reports for each genome (Tables S1 and S2) [96]. These Kraken reports were then run through Krona Pie Chart (via Galaxy Version 1.14.6), which allows for a representation of the taxonomic classifications of a genome via an interactive pie chart (Figs S1 and S2) [97].
Spore production protocol
B. subtilis BG01-4TM and the control B. subtilis HU58 (Table S1), a known spore producer, were plated on both 2× Schaeffer-Glucose (2× SG) agar (Table S5) and incubated at 37 °C (Protocol 1.4).
Spore examination protocol
Both BG01-4TM and HU58 were examined at 24 h periods (for 3–4 days) via the Schaeffer–Fulton microscopic staining protocol to determine if the culture was only just vegetive cells, or if the commencement of sporulation had occurred, which would be seen by the presence of endospores and/or free-spores in the sample (Protocol 1.5). Plates of both BG01-4TM and HU58 were examined via the Schaeffer–Fulton microscopic staining protocol (Table S6) at 24 h timepoints until free-spores make up >90 % of the culture, or until commitment and production of spores had not occurred. A failure to induce sporulation will be noted at a timepoint of approximately 96–120 h (4–5 days) with no spores being present in either endospore or free-spore form, and the vegetative cells have begun to perish due to nutrient exhaustion and the culture is predominantly cellular debris (Figs S3–S6).
Spore purification protocol
The spores produced by BG01-4TM and the control HU58 were extracted and purified by a protocol previously described [105, 105]. Adjustments to the protocol were made and included the use of a 4 °C freezer room in lieu of a 3 °C freezer room. Heat treatment of spores may be necessary after resuspending washed spores in 0.1 % lysozyme + phosphate buffer (Table S7) to completely eradicate vegetative cells. Heat treatment was done by heating the spore suspension in a 70–75 °C water bath for 10 min (Protocol 1.6)
Spore quantification protocol
Once the spores produced by BG01-4TM and the control HU58 had been purified, the quantity of spores being produced by both isolates was determined through the use of a haemocytometer (haemocytometer loading instructions: Fig. S7; haemocytometer quantifying instructions: Fig. S8) and light microscope. Amendments were made to the protocols given in other studies due to the use of a light microscope rather than a phase-contrast microscope. In this study, under a light microscope, the spores were required to be stained to be examined (Protocol 1.7).
Selecting for sporulation defective mutations in BG01-4TM isolates
BG01-4TM was grown independently 15 times on 15 differently modified types of Luria–Bertani (LB) agar with different glucose molarity (200, 400 and 600 mM) and pH levels (pH 5–9) (Table S8) for multiple generations over 14 days (~400 generations) (Table S9). Over the course of the mutation selection protocol (14 days), the amount of growth by BG01-4TM was recorded prior to daily re-inoculations. The level of growth by BG01-4TM over a range of glucose molarities (200, 400 and 600 mM) and pH levels (pH 5–9) was determined as the high sugar levels and pH range of pH 5–9 are reminiscent of conditions found within the infant gastrointestinal tract. The amount of growth was measured by the extent of growth across the plate within 24 h: total plate coverage 90–100 %; growth on all streaks 70–90 %; growth on 2/3 streaks 50–69 %; growth on 1/3 streaks 20–49 %; growth on inoculation site 5–19 %; no growth 0 %.
This experiment was done in triplicate for a total of 45 isolates. The 45 isolates of BG01-4TM (triplicates) were grown at 37 °C on one of the 15 types of media (i.e. pH 7, 400 mM), with the isolates being plated onto the same type of plate after 18–24 h of growth for 14 days. Information about media production is given in the media section. The serial batch culture procedure was done aseptically. Prior to and after each inoculation of BG01-4TM with the wired loop, the wired loop was flamed for 5–10 s with a Bunsen burner to ensure the removal of any bacterial culture from the loop. From the serial batch culture, hypothetically 45 new strains of B. subtilis have been produced and are accordingly labelled below (Table S9).
BG01-4TM was inoculated onto a Day 1 LB agar plate via streak dilution, with a specific pH (pH 5–9) and glucose molarity (i.e. pH 7–400 mM), and incubated at 37 °C for 18–24 h (this was replicated three times for each isolate and media type).
After 18–24 h of growth BG01-4TM was isolated from the plate (from a single colony – if not possible, the edges of a larger colony) and re-inoculated onto a new corresponding LB agar plate and incubated again at 37 °C for 18–24 h (i.e. Day 1 pH 7–400 mM → Day 2 pH 7–400 mM).
Step 2 was repeated for the 15 isolates and 15 types of media until the completion of Day 14 (Table S9).
After 14 days of continuous growth, the 15 isolates were removed from the plates via scraping the colonies to the edge of the plate with an aseptic wired loop and pipetting LB broth onto the scraped colonies and re-pipetting up the LB broth to remove the colonies.
The 15 isolates were pipetted into tubes labelled with the specific strain and replicate names and stored separately in 1400 µl of LB broth and 600 µl glycerol (30 % glycerol) to ensure cells do not perish during storage in the −80 °C freezer. Tubes were vortexed prior to freezing.
Results and discussion
BG01-4TM is a spore former
BG01-4TM has been established as a spore former, producing spores in response to glucose exhaustion after 92 h when cultured on 2× SG agar (Fig. 1). The B. subtilis isolate BG01-4TM was expected to be capable of sporulation, as past studies have revealed as many as 500 genes are expressed by B. subtilis during sporulation [72].
Fig. 1.
Image of spore, endospore and vegetative cell forms of Bacillus subtilis BG01-4TM. Cultured on 2× SG agar for 92 h; ×1000 magnification. Spores and endospores are stained with malachite green stain and appear light blue/green; vegetative cells are stained with safranin and appear pink/red.
Once BG01-4TM was determined to form spores in response to nutrient exhaustion, the efficacy of BG01-4TM to execute the process of sporulation was assessed by quantifying the spores produced by BG01-4TM at a specific time-point, compared with a commercially available and known spore-forming probiotic strain, B. subtilis HU58 [73]. BG01-4TM demonstrated a greater capacity to produce spores than HU58, calculated via a haemocytometer after 92 h of growth on 2× SG agar, with the BG01-4TM sample observed to contain 37 000 000 spores ml–1 (3.7×107 c.f.u. ml−1), and the HU58 sample containing 27 000 000 spores ml–1 (2.7×107 c.f.u. ml−1) [74, 75]. These results did not indicate a major disparity in the number of spores produced by BG01-4TM and HU58 over 92 h, but the number of spores produced by both BG01-4TM and HU58 were seen to be considerably lower than a previously quantified laboratory strain, B. subtilis 1012 (6.7×108 c.f.u. ml−1 after 72 h) [52]. However, a variation in the number of spores produced by a strain of B. subtilis is expected to occur from strain to strain, and also past studies have established that a fluctuation in the number of spores produced by B. subtilis will be seen on different types of media used to illicit sporulation (solid or liquid) and the original number of cells used to inoculate the culture [52]. Earlier B. subtilis spore quantification experiments also determined the method of spore purification to be a factor affecting the sum of spores quantified, but the lysozyme spore purification method used in this study has been regarded as one of the most effective with regard to spore purity and yield (Protocol 1.6) [52, 94].
BG01-4TM growth patterns in non-sporulation selective media
As a result of BG01-4TM expressing the phenotypic ability to produce spores in response to nutrient exhaustion, we attempted to develop a non-GMO BG01-4TM variant with the inability to develop spores. B. subtilis sporulation has been extensively studied throughout the literature, revealing environmental glucose and pH levels as key factors affecting sporulation in B. subtilis isolates [66–71]. As past studies have indicated the negative effects on sporulation of high levels of glucose and a pH<6, a medium was developed utilizing these factors as epigenetic constraints against sporulation [88–93].
The mutation selection protocol of BG01-4TM on LB agar with varying glucose molarities (200, 400 and 600 mM) and pH levels (pH 5–9) did not only provide the potential for a non-spore forming BG01-4TM mutant to be isolated, but also the high glucose levels and relevant pH range provided the opportunity to understand where within the intestinal environment BG01-4TM is most likely to thrive [106–115]. Throughout the entire selection culture (14 days) the level of growth after 24 h on the plate by the BG01-4TM isolates was recorded, to determine under what glucose molarity and pH level BG01-4TM exhibited the best growth (Fig. 2a–e).
Fig. 2.
Percentage growth by Bacillus subtilis BG01-4TM in 24 h on LB agar with excess glucose (glucose molarities: 200 mM – blue, 400 mM – green, 600 mM – red), recorded over a time period of 14 days (14 agar plates). (a) Growth at pH 5; (b) growth at pH 6; (c) growth at pH 7; (d) growth at pH 8; (e) growth at pH 9.
BG01-4TM was observed across all glucose molarities (200, 400 and 600 mM) and pH levels (pH 5–9) to have the lowest growth for each respective media type during the first 1–2 days after the initial inoculation (Fig. 2a–e). And again, across all glucose molarities and pH levels, BG01-4TM demonstrated an increased growth rate for each respective media type as the day of the experiment (plate number) increased (Fig. 2a–e). BG01-4TM expressed the best growth at pH 7 for all glucose molarities, establishing pH 7 as the optimum pH for BG01-4TM growth (Fig. 2c). The high growth rate of BG01-4TM at pH 7 is in line with other studies that have indicated that the optimum growth pH of B. subtilis is within the pH range 7–8 [90]. Our results further ratify a range of pH 7–8 as being the ideal pH for B. subtilis growth, as BG01-4TM also demonstrated a high level of growth at pH 8 for all glucose molarities (Fig. 2d). Analysis of BG01-4TM growth during the serial batch culture indicates that, intestinally, BG01-4TM will demonstrate the highest rates of growth within the small and large intestines, which have been established to have pH ranges of pH 4–7 (Fig. 2a–e) [93, 116]. The results also suggest that at pH 7 the level of luminal glucose will not affect the rate of growth by BG01-4TM, which indicates that BG01-4TM growth intestinally will not be greatly affected by the fluctuating glucose levels at pH 7 (Fig. 2c).
Considerable levels of growth were still exhibited by BG01-4TM outside of the optimum pH range (pH 7 –8) at pH 6 and 9, with a higher growth by BG01-4TM oberved at pH 6 than at pH 9 (Fig. 2b, c). Outside of the optimum pH range, an increase in glucose molarity was seen to be a factor in restricting BG01-4TM growth, with 600 mM glucose at pH 6 limiting growth by ~20 %, and 400 and 600 mM glucose at pH 9 both also limiting growth by ~20 % (Fig. 2b, c). The negative effects of increasing glucose molarity on BG01-4TM growth were only observed outside the optimum pH range (pH 7–8) and indicates that BG01-4TM growth intestinally may be greatly impacted at pH<7 l or >8 during the following 1–2 h after feeding, as post-meal consumption will result in an increase of luminal glucose [110]. The negative impact of rising glucose molarity on BG01-4TM growth outside of the pH range 7–8 suggests that if BG01-4TM is consumed at around the same time as a meal, growth of BG01-4TM outside of the optimum pH range (7–8) will be greatly impeded by the high luminal glucose levels [93, 116, 117]. Moreover, BG01-4TM expressed the lowest growth rates at pH 5, with an increasing glucose molarity observed to further restrict growth (Fig. 2a). The growth levels of BG01-4TM at pH five for all glucose molarities indicates that survival rate of BG01-4TM within the stomach will be poor, and subsequently the level of viable BG01-4TM vegetative cells which are able to pass through the stomach to the small intestines will be low (Fig. 2a) [102].
Inability to knock-out sporulation in BG01-4TM
In order to create a non-GMO B. subtilis incapable of developing spores, the epigenetic factors surrounding sporulation in B. subtilis must be understood [118, 119]. The key genes involved in sporulation are upregulated by B. subtilis in response to a lack of nutrients, predominantly glucose, given that B. subtilis isolates demonstrated a lower rate of sporulation in environments with high levels of glucose [105, 120, 121]. Various studies have confirmed the involvement of glucose in the commitment to sporulation by B. subtilis , with glucose being classified as an inhibitor of sporulation and the lack of glucose an activator of sporulation in B. subtilis [88–91]. Transcriptional analysis of B. subtilis genes involved in sporulation has also revealed the negative effects of extreme pH on the expression of sporulation genes in B. subtilis [92, 93]. A study by Cosby et al. [91] revealed a lower level of sporulation by B. subtilis when cultured at a low pH (~pH 5) due to the decreased activity of the transcriptional factor Sigma H (sigH), and the subsequent decline in the transcription of sigH-dependent sporulation genes [92]. External glucose levels and pH have been seen to be environmental factors involved in sporulation by B. subtilis and have been proven to directly affect the levels of sporulation, with high environmental glucose and low pH observed to reduce sporulation in B. subtilis [88–93]. After 14 days of serial batch culture on the glucose and pH modified LB agar, the BG01-4TM isolates (1–44, 47) (with the exception of isolates 18 and 33, which perished during the serial batch culture) were plated on 2× SG agar and it was found that all of the tested BG01-4TM isolates (1–17, 19–31, 33–44, 47) had retained the ability to produce spores in response to nutrient exhaustion (Table S9).
The process of sporulation in microbes is a key survival mechanism, and in B. subtilis can involve the expression of over 500 genes [122]. The production of a spore by bacteria is seen to be a highly conserved system, even across different distantly divergent genera of bacteria, including Bacillus spp. and Clostridium spp. [72, 123, 124]. A list constructed by Stragier et al. [125] demonstrates that although variation may occur in sporulation genes, there are genes which control essential steps in the development of a spore that are highly conserved across spore-forming Bacilli and Clostridia , such as genes involved in: pre-septation, post-septation, post-engulfment and spore-coat development [73, 107, 108]. The conservation of these core sporulation genes across members of Bacillus spp. and Clostridium spp., with a most recent common ancestor ~2.3 billion years ago, indicates the robustness of these genes involved in sporulation and suggests the unlikelihood of these bacteria losing these essential sporulation genes via natural processes [125]. A reason for the preservation of these fundamental sporulation genes may be in part due to the ongoing requirement of members of the genera Bacillus and Clostridium to produce spores in order to survive adverse environmental conditions [122, 125, 126]. However, the high level of conserved sporulation genes could also be attested to by the fact that during the normal vegetative growth stage the majority of sporulation genes are inactive and not being expressed, which may suggest that sporulation genes are not subject to genetic recombination and mutation during the vegetative state [125, 127]. The dormancy of sporulation genes during the normal growth stage of B. subtilis vegetative cells may be indicative of the inability to knock-out sporulation genes via mutation accumulation and selection protocols utilizing serial batch culture with high levels of glucose, which is designed to ensure the inactivity of sporulation genes [88, 105, 120, 121].
BG01-4-8 regulates sporulation less than BG01-4TM
Although the development of a non-sporulating BG01-4TM mutant was unsuccessful, a variation in the rate of sporulation by the isolate BG01-4-8 did occur (Fig. 3). All three BG01-4-8 replicates were observed to produce spores within 24 h of inoculation on 2× SG agar (Fig. S9), ~48 h faster than the parent strain replicates, BG01-4TM, indicating that a potential genetic mutation has occurred regarding sporulation genes from BG01-4TM to BG01-4-8 (Fig. 3) (Table S9; Figs S9 and S10).
Fig. 3.
Spore, endospore and vegetative cell forms of Bacillus subtilis BG01-4-8. Cultured on 2× SG agar for 24 h; ×1000 magnification. Spores and endospores are stained with malachite green stain and appear light blue/green; vegetative cells are stained with safranin and appear pink/red.
Only BG01-4-8 and the positive control, B. subtilis HU58, were found to produce spores in response to nutrient exhaustion within 24 h, whilst BG01-4TM and the other BG01-4TM test isolates were observed to have produced spores after ~72 h (Table S9; Figs S9 and S10). The disparity in the rate of sporulation between BG01-4-8 and the other BG01-4TM isolates indicates that the genetic variation which has occurred must involve genes that pertain to the regulation of the initiation of sporulation [88, 89, 128]. More precisely, as this experiment was conducted on media conducive to inducing sporulation via nutrient exhaustion, the mutation is expected to have occurred in genes involved in regulating the initiation of sporulation in response to nutrient exhaustion [88, 89, 128]. The sporulation killing factor (skf) and the sporulation delay operon (sdpABC) are expressed by B. subtilis to produce and export toxins (skfA and sdpC) extracellularly, which regulate community-level sporulation by targeting and killing other B. subtilis cells and limiting the number of cells entering sporulation [129–131]. The actions of these extracellular sporulation regulatory operons (skf and sdp) have been shown to decrease the rate of sporulation initiation when compared with B. subtilis mutants for the skf and sdp operons [129–132]. The skf and sdp operons slow down the initiation of sporulation by B. subtilis in two ways: by lysing vegetative cells with the potential to produce spores, and also by increasing the available nutrients for the vegetative cells which are not targeted, as lysed vegetative cells release cellular contents, in turn delaying nutrient exhaustion [129–131].
Genomic analysis determined that the BG01-4TM genome contains the sdp operon, whilst being a mutant for the skf operon (Table S10). This indicates that BG01-4TM will have a greater overall regulation of sporulation than BG01-WT, which was found to be a double mutant for sdp and skf [129–132]. A faster rate of sporulation is expected in the single mutant (skf) BG01-4TM over the double mutant (skf and sdp) BG01-WT, as a previous study revealed faster rates of sporulation by B. subtilis with deletions in both the skf and sdp operons, compared with B. subtilis isolates with one complete skf or sdp operon [129]. As a mutation in the sdp operon has occurred previously in a serial batch culture protocol of BG01-4TM from the parent strain, BG01-WT, it is possible that the sdp gene may have again been subject to a mutation during the serial batch culture of BG01-4-8 from BG01-4TM. If a deletion mutation has occurred in the sdp operon in BG01-4-8, BG01-4-8 will have become a double mutant for skf and sdp, which would be indicative of the ~48 h quicker commitment to sporulation observed by BG01-4-8 than BG01-4TM, which is only a single mutant for skf [129–132]. Although a previous study established the faster initiation of sporulation in response to nutrient exhaustion by B. subtilis skf and sdp double mutants than single mutants, to definitively determine the reason behind the ~48 h quicker initiation of sporulation by BG01-4-8 by ~48 h, the BG01-4-8 genome must be analysed and compared with the genome of BG01-4TM to determine what genetic variation has occurred [129].
Concluding remarks
A more accurate way to knock-out sporulation in BG01-4TM may be required, due to the intrinsically conserved nature of core sporulation genes, even across genera of bacteria. Such methods have had pronounced results, in some cases limiting sporulation and even knocking out essential genes for sporulation in some B. subtilis mutants [133, 134]. Although often the development of genetic variant strains of bacteria, including B. subtilis, involves genome editing protocols that would classify the emerging isolate as a GMO, recent methods which utilize PCR have been proven to effectively amplify specific sections of DNA without certain genes, and are not deemed to be GMOs. Such advances and lack of public scrutiny regarding the use of these protocols suggest the potential to develop a non-spore-forming BG01-4TM strain through the use of directed PCR methods [134, 135]. Due to the robustness of sporulation genes within the genome, the use of genetic engineering protocols may be the most effective way of creating a B. subtilis isolate that is incapable of sporulation [72, 122–124, 135, 136]. There are various genes within the B. subtilis genome that could be targeted to create a non-sporulating phenotype, but the genes which would most effectively negate sporulation in B. subtilis if removed or modified would be spo0A, the sporulation master regulon which has already been proven to create a sporulation null B. subtilis isolate when removed, and abrB, which is also another key transcriptional regulator in B. subtilis, allowing B. subtilis to shift its genome expression from a vegetive state to a sporulation state [137–140]. The removal or modification of either spo0A or abrB would affect the transcription of most sporulation genes, due to the fact that spo0A and abrB are seen to control the transcription of sporulation genes directly and indirectly in B. subtilis [137–140].
Supplementary Data
Funding information
This work was supported by a La Trobe University Postgraduate Research Scholarship. This work received funding from the Australian Government Department of Industry, Innovation and Science and Vernx Biotechnology. The funders had no role in study design, data collection or the decision to submit the work for publication.
Acknowledgements
L.M.B.: I extend thanks to my collaborator Dr Anya Shindler, my La Trobe University supervisors Dr Anya Shindler, Dr Jennifer Wood, Prof. Ashley Franks, and my Vernx supervisor Prof. Craig Patch. I would also like extend a further thanks to Craig and everyone at Vernx for allowing me to take on such an interesting and important study, and entrusting me with their product, BG01-4TM.
Author contributions
L.M.B., A.E.S., C.P., A.E.F.: Conceptualization, Methodology, Software. L.M.B.: Data curation, Writing – Original draft preparation. L.M.B.: Visualization, Investigation. A.E.S., J.W., C.P., A.E.F.: Supervision. L.M.B., A.E.S., A.E.F.: Software, Validation. A.E.S., J.W., C.P., A.E.F.: Writing- Reviewing and Editing.
Conflicts of interest
C.P. is the Executive Chairman, CEO of Vernx Biotechnology Pty Ltd. A.F. and E.H. act on the scientific advisory panel of Vernx Biotechnology Pty Ltd.
Footnotes
Abbreviations: BCFA, branched chain fatty acid; GMO, genetically modified organism; NEC, necrotizing enterocolitis; SCFA, short chain fatty acid; 2x SG, 2x Schaeffer-Glucose.
Ten supplementary figures, ten supplementary tables and three supplementary informations are available with the online version of this article.
References
- 1.Ran-Ressler RR, Khailova L, Arganbright KM, Adkins-Rieck CK, Jouni ZE, et al. Branched chain fatty acids reduce the incidence of necrotizing enterocolitis and alter gastrointestinal microbial ecology in a neonatal rat model. PLoS One. 2011;6:e29032. doi: 10.1371/journal.pone.0029032. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Lin PW, Stoll BJ. Necrotising enterocolitis. Lancet. 2006;368:1271–1283. doi: 10.1016/S0140-6736(06)69525-1. [DOI] [PubMed] [Google Scholar]
- 3.Bell MJ, Ternberg JL, Feigin RD, Keating JP, Marshall RI, et al. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Ann Surg. 1978;187:1–7. doi: 10.1097/00000658-197801000-00001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Aagaard K, Ma J, Antony KM, Ganu R, Petrosino J, et al. The placenta harbors a unique microbiome. Sci Transl Med. 2014;6:237ra65. doi: 10.1126/scitranslmed.3008599. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.He Q, Kwok LY, Xi X, Zhong Z, Ma T, et al. The meconium microbiota shares more features with the amniotic fluid microbiota than the maternal fecal and vaginal microbiota. Gut Microbes. 2020;12:1794266. doi: 10.1080/19490976.2020.1794266. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Collado MC, Rautava S, Aakko J, Isolauri E, Salminen S. Human gut colonisation may be initiated in utero by distinct microbial communities in the placenta and amniotic fluid. Sci Rep. 2016;6:23129. doi: 10.1038/srep23129. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Ferretti P, Pasolli E, Tett A, Asnicar F, Gorfer V, et al. Mother-to-infant microbial transmission from different body sites shapes the developing infant gut microbiome. Cell Host Microbe. 2018;24:133–145. doi: 10.1016/j.chom.2018.06.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Ríos-Covián D, Ruas-Madiedo P, Margolles A, Gueimonde M, de Los Reyes-Gavilán CG, et al. Intestinal short chain fatty acids and their link with diet and human health. Front Microbiol. 2016;7:185. doi: 10.3389/fmicb.2016.00185. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Yan Y, Wang Z, Wang D, Lawrence P, Wang X, et al. BCFA-enriched vernix-monoacylglycerol reduces LPS-induced inflammatory markers in human enterocytes in vitro. Pediatr Res. 2018;83:874–879. doi: 10.1038/pr.2017.297. [DOI] [PubMed] [Google Scholar]
- 10.Nishijima K, Yoneda M, Hirai T, Takakuwa K, Enomoto T. Biology of the vernix caseosa: A review. J Obstet Gynaecol Res. 2019;45:2145–2149. doi: 10.1111/jog.14103. [DOI] [PubMed] [Google Scholar]
- 11.Visscher MO, Hoath SB. Treatment of Dry Skin Syndrome. Berlin, Heidelberg: Springer; 2012. Vernix caseosa and its substitutes: lipid composition and physicochemical properties; pp. 193–213. [DOI] [Google Scholar]
- 12.Ran-Ressler RR, Glahn RP, Bae S, Brenna JT. Branched-chain fatty acids in the neonatal gut and estimated dietary intake in infancy and adulthood. Nestle Nutr Inst Workshop Ser. 2013;77:133–143. doi: 10.1159/000351396. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Ran-Ressler RR, Devapatla S, Lawrence P, Brenna JT. Branched chain fatty acids are constituents of the normal healthy newborn gastrointestinal tract. Pediatr Res. 2008;64:605–609. doi: 10.1203/PDR.0b013e318184d2e6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Cong X, Xu W, Janton S, Henderson WA, Matson A, et al. Gut microbiome developmental patterns in early life of preterm infants: impacts of feeding and gender. PLoS One. 2016;11:e0152751. doi: 10.1371/journal.pone.0152751. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Rinninella E, Raoul P, Cintoni M, Franceschi F, Miggiano GAD, et al. What is the healthy gut microbiota composition? a changing ecosystem across age, environment, diet, and diseases. Microorganisms. 2019;7:14. doi: 10.3390/microorganisms7010014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Stewart CJ, Embleton ND, Marrs ECL, Smith DP, Fofanova T, et al. Longitudinal development of the gut microbiome and metabolome in preterm neonates with late onset sepsis and healthy controls. Microbiome. 2017;5:1–11. doi: 10.1186/s40168-017-0295-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Zhou Y, Shan G, Sodergren E, Weinstock G, Walker WA, et al. Longitudinal analysis of the premature infant intestinal microbiome prior to necrotizing enterocolitis: a case-control study. PLoS One. 2015;10:e0118632. doi: 10.1371/journal.pone.0118632. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Hagen PC, Skelley JW. Efficacy of Bifidobacterium species in prevention of necrotizing enterocolitis in very-low birth weight infants. A systematic review. J Pediatr Pharmacol Ther. 2019;24:10–15. doi: 10.5863/1551-6776-24.1.10. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Morrow AL, Lagomarcino AJ, Schibler KR, Taft DH, Yu Z, et al. Early microbial and metabolomic signatures predict later onset of necrotizing enterocolitis in preterm infants. Microbiome. 2013;1:1–16. doi: 10.1186/2049-2618-1-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Coggins SA, Wynn JL, Weitkamp J-H. Infectious causes of necrotizing enterocolitis. Clin Perinatol. 2015;42:133–154. doi: 10.1016/j.clp.2014.10.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Hoffmann KM, Deutschmann A, Weitzer C, Joainig M, Zechner E, et al. Antibiotic-associated hemorrhagic colitis caused by cytotoxin-producing Klebsiella oxytoca . Pediatrics. 2010;125:e960–e963. doi: 10.1542/peds.2009-1751. [DOI] [PubMed] [Google Scholar]
- 22.Denning N-L, Prince JM. Neonatal intestinal dysbiosis in necrotizing enterocolitis. Mol Med. 2018;24:1–10. doi: 10.1186/s10020-018-0002-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Paveglio S, Ledala N, Rezaul K, Lin Q, Zhou Y, et al. Cytotoxin-producing Klebsiella oxytoca in the preterm gut and its association with necrotizing enterocolitis. Emerg Microbes Infect. 2020;9:1321–1329. doi: 10.1080/22221751.2020.1773743. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Olm MR, Bhattacharya N, Crits-Christoph A, Firek BA, Baker R, et al. Necrotizing enterocolitis is preceded by increased gut bacterial replication, Klebsiella, and fimbriae-encoding bacteria. Sci Adv. 2019;5:eaax5727. doi: 10.1126/sciadv.aax5727. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Cassir N, Simeoni U, La Scola B. Gut microbiota and the pathogenesis of necrotizing enterocolitis in preterm neonates. Future Microbiol. 2016;11:273–292. doi: 10.2217/fmb.15.136. [DOI] [PubMed] [Google Scholar]
- 26.Kiu R, Hall LJ. An update on the human and animal enteric pathogen Clostridium perfringens. Emerg Microbes Infect. 2018;7:141. doi: 10.1038/s41426-018-0144-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Laursen MF. Gut microbiota development: influence of diet from infancy to toddlerhood. Ann Nutr Metab. 2021;77:21–34. doi: 10.1159/000517912. [DOI] [PubMed] [Google Scholar]
- 28.Cho SX, Rudloff I, Lao JC, Pang MA, Goldberg R, et al. Characterization of the pathoimmunology of necrotizing enterocolitis reveals novel therapeutic opportunities. Nat Commun. 2020;11:1–9. doi: 10.1038/s41467-020-19400-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Zheng N, Gao Y, Zhu W, Meng D, Walker WA. Short chain fatty acids produced by colonizing intestinal commensal bacterial interaction with expressed breast milk are anti-inflammatory in human immature enterocytes. PLoS One. 2020;15:e0229283. doi: 10.1371/journal.pone.0229283. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Schreurs RRCE, Baumdick ME, Sagebiel AF, Kaufmann M, Mokry M, et al. Human fetal TNF-α-cytokine-producing CD4+ effector memory T cells promote intestinal development and mediate inflammation early in life. Immunity. 2019;50:462–476. doi: 10.1016/j.immuni.2018.12.010. [DOI] [PubMed] [Google Scholar]
- 31.Werts AD, Fulton WB, Ladd MR, Saad-Eldin A, Chen YX, et al. A novel role for necroptosis in the pathogenesis of necrotizing enterocolitis. Cell Mol Gastroenterol Hepatol. 2020;9:403–423. doi: 10.1016/j.jcmgh.2019.11.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Arboleya S, Binetti A, Salazar N, Fernández N, Solís G, et al. Establishment and development of intestinal microbiota in preterm neonates. FEMS Microbiol Ecol. 2012;79:763–772. doi: 10.1111/j.1574-6941.2011.01261.x. [DOI] [PubMed] [Google Scholar]
- 33.Warner BB, Deych E, Zhou Y, Hall-Moore C, Weinstock GM, et al. Gut bacteria dysbiosis and necrotising enterocolitis in very low birthweight infants: a prospective case-control study. Lancet. 2016;387:1928–1936. doi: 10.1016/S0140-6736(16)00081-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Mai V, Young CM, Ukhanova M, Wang X, Sun Y, et al. Fecal microbiota in premature infants prior to necrotizing enterocolitis. PLoS One. 2011;6:e20647. doi: 10.1371/journal.pone.0020647. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Dardas M, Gill SR, Grier A, Pryhuber GS, Gill AL, et al. The impact of postnatal antibiotics on the preterm intestinal microbiome. Pediatr Res. 2014;76:150–158. doi: 10.1038/pr.2014.69. [DOI] [PubMed] [Google Scholar]
- 36.Bury RG, Tudehope D. Enteral antibiotics for preventing necrotizing enterocolitis in low birthweight or preterm infants. Cochrane Database Syst Rev. 2001;2001:CD000405. doi: 10.1002/14651858.CD000405. [DOI] [PubMed] [Google Scholar]
- 37.Pammi M, Cope J, Tarr PI, Warner BB, Morrow AL, et al. Intestinal dysbiosis in preterm infants preceding necrotizing enterocolitis: a systematic review and meta-analysis. Microbiome. 2017;5:31. doi: 10.1186/s40168-017-0248-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Li Y, Shen RL, Ayede AI, Berrington J, Bloomfield FH, et al. Early use of antibiotics is associated with a lower incidence of necrotizing enterocolitis in preterm, very low birth weight infants: the NEOMUNE-NeoNutriNet cohort study. J Pediatr. 2020;227:128–134. doi: 10.1016/j.jpeds.2020.06.032. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Maier L, Goemans CV, Wirbel J, Kuhn M, Eberl C, et al. Unravelling the collateral damage of antibiotics on gut bacteria. Nature. 2021;599:120–124. doi: 10.1038/s41586-021-03986-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Alexander VN, Northrup V, Bizzarro MJ. Antibiotic exposure in the newborn intensive care unit and the risk of necrotizing enterocolitis. J Pediatr. 2011;159:392–397. doi: 10.1016/j.jpeds.2011.02.035. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Hartantyo SHP, Chau ML, Koh TH, Yap M, Yi T, et al. Foodborne Klebsiella pneumoniae: virulence potential, antibiotic resistance, and risks to food safety. J Food Prot. 2020;83:1096–1103. doi: 10.4315/JFP-19-520. [DOI] [PubMed] [Google Scholar]
- 42.Baghani A, Ghourchian S, Aliramezani A, Yaseri M, Mesdaghinia A, et al. Highly antibiotic-resistant Clostridium difficile isolates from Iranian patients. J Appl Microbiol. 2018;125:1518–1525. doi: 10.1111/jam.14035. [DOI] [PubMed] [Google Scholar]
- 43.Paredes-Sabja D, Shen A, Sorg JA. Clostridium difficile spore biology: sporulation, germination, and spore structural proteins. Trends Microbiol. 2014;22:406–416. doi: 10.1016/j.tim.2014.04.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Jiang YN, Muk T, Stensballe A, Nguyen DN, Sangild PT, et al. Early protein markers of necrotizing enterocolitis in plasma of preterm pigs exposed to antibiotics. Front Immunol. 2020;11:565862. doi: 10.3389/fimmu.2020.565862. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Schanler RJ. Probiotics and necrotising enterocolitis in premature infants. Arch Dis Child Fetal Neonatal Ed. 2006;91:F395–7. doi: 10.1136/adc.2005.092742. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Silverman MA, Konnikova L, Gerber JS. Impact of antibiotics on necrotizing enterocolitis and antibiotic-associated diarrhea. Gastroenterol Clin North Am. 2017;46:61–76. doi: 10.1016/j.gtc.2016.09.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Schwiertz A, Gruhl B, Löbnitz M, Michel P, Radke M, et al. Development of the intestinal bacterial composition in hospitalized preterm infants in comparison with breast-fed, full-term infants. Pediatr Res. 2003;54:393–399. doi: 10.1203/01.PDR.0000078274.74607.7A. [DOI] [PubMed] [Google Scholar]
- 48.Wang S, Yu J, Suvira M, Setlow P, Li Y. Uptake of and resistance to the antibiotic berberine by individual dormant, germinating and outgrowing Bacillus spores as monitored by laser tweezers raman spectroscopy. PLoS One. 2015;10:e0144183. doi: 10.1371/journal.pone.0144183. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Wauters L, Slaets H, De Paepe K, Ceulemans M, Wetzels S, et al. Efficacy and safety of spore-forming probiotics in the treatment of functional dyspepsia: a pilot randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol Hepatol. 2021;6:784–792. doi: 10.1016/S2468-1253(21)00226-0. [DOI] [PubMed] [Google Scholar]
- 50.Hong HA, Huang JM, Khaneja R, Hiep LV, Urdaci MC, et al. The safety of Bacillus subtilis and Bacillus indicus as food probiotics. J Appl Microbiol. 2008;105:510–520. doi: 10.1111/j.1365-2672.2008.03773.x. [DOI] [PubMed] [Google Scholar]
- 51.Duc LH, Hong HA, Barbosa TM, Henriques AO, Cutting SM. Characterization of Bacillus probiotics available for human use. Appl Environ Microbiol. 2004;70:2161–2171. doi: 10.1128/AEM.70.4.2161-2171.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Tavares Batista M, Souza RD, Paccez JD, Luiz WB, Ferreira EL, et al. Gut adhesive Bacillus subtilis spores as a platform for mucosal delivery of antigens. Infect Immun. 2014;82:1414–1423. doi: 10.1128/IAI.01255-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Angioi A, Zanetti S, Sanna A, Delogu G, Fadda G. Adhesiveness of Bacillus subtilis Strains to Epithelial Cells Cultured in vitro. Microb Ecol Health Dis. 1995;8:71–77. doi: 10.3109/08910609509141385. [DOI] [Google Scholar]
- 54.Alebouyeh M, Behzadian-Nejad Q, Soleimani M, Hassan ZM, Salmanian AH, et al. Characterization of the interaction of undomesticated Bacillus subtilis spores with Caco-2 cell line. Ann Microbiol. 2009;59:273–277. doi: 10.1007/BF03178328. [DOI] [Google Scholar]
- 55.Kaneda T. Fatty acids of the genus Bacillus: an example of branched-chain preference. Bacteriol Rev. 1977;41:391–418. doi: 10.1128/br.41.2.391-418.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Diomandé SE, Nguyen-The C, Guinebretière M-H, Broussolle V, Brillard J. Role of fatty acids in Bacillus environmental adaptation. Front Microbiol. 2015;6:813. doi: 10.3389/fmicb.2015.00813. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Ríos-Covián D, Ruas-Madiedo P, Margolles A, Gueimonde M, de Los Reyes-Gavilán CG, et al. Intestinal short chain fatty acids and their link with diet and human health. Front Microbiol. 2016;7:185. doi: 10.3389/fmicb.2016.00185. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Hong HA, Khaneja R, Tam NMK, Cazzato A, Tan S, et al. Bacillus subtilis isolated from the human gastrointestinal tract. Res Microbiol. 2009;160:134–143. doi: 10.1016/j.resmic.2008.11.002. [DOI] [PubMed] [Google Scholar]
- 59.Higgins D, Dworkin J. Recent progress in Bacillus subtilis sporulation. FEMS Microbiol Rev. 2012;36:131–148. doi: 10.1111/j.1574-6976.2011.00310.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Galbraith H, Miller TB. Physicochemical effects of long chain fatty acids on bacterial cells and their protoplasts. J Appl Bacteriol. 1973;36:647–658. doi: 10.1111/j.1365-2672.1973.tb04150.x. [DOI] [PubMed] [Google Scholar]
- 61.Rice KC, Bayles KW. Molecular control of bacterial death and lysis. Microbiol Mol Biol Rev. 2008;72:85–109. doi: 10.1128/MMBR.00030-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Casula G, Cutting SM. Bacillus probiotics: spore germination in the gastrointestinal tract. Appl Environ Microbiol. 2002;68:2344–2352. doi: 10.1128/AEM.68.5.2344-2352.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Frewer L, Lassen J, Kettlitz B, Scholderer J, Beekman V, et al. Societal aspects of genetically modified foods. Food Chem Toxicol. 2004;42:1181–1193. doi: 10.1016/j.fct.2004.02.002. [DOI] [PubMed] [Google Scholar]
- 64.Kamaldeen S, Powell DA. Public perceptions of biotechnology. Food Safety Network Technical Report. 2000;17:1–6. vol. [Google Scholar]
- 65.Husby J. Definitions of GMO/LMO and modern biotechnology. Biosafety first. Trondheim: Tapir Academic Publishers; 2007. [Google Scholar]
- 66.Kanchiswamy CN, Malnoy M, Velasco R, Kim JS, Viola R. Non-GMO genetically edited crop plants. Trends Biotechnol. 2015;33:489–491. doi: 10.1016/j.tibtech.2015.04.002. [DOI] [PubMed] [Google Scholar]
- 67.Gramelsberger G. Continuous culture techniques as simulators for standard cells: Jacques Monod’s, Aron Novick’s and Leo Szilard’s quantitative approach to microbiology. Hist Philos Life Sci. 2018;40:1–23. doi: 10.1007/s40656-017-0182-x. [DOI] [PubMed] [Google Scholar]
- 68.James TW. Continuous culture of microorganisms. Annu Rev Microbiol. 1961;15:27–46. doi: 10.1146/annurev.mi.15.100161.000331. [DOI] [Google Scholar]
- 69.Esteller M. Epigenetics in evolution and disease. The Lancet. 2008;372:S90–S96. doi: 10.1016/S0140-6736(08)61887-5. [DOI] [Google Scholar]
- 70.Berger SL, Kouzarides T, Shiekhattar R, Shilatifard A. An operational definition of epigenetics. Genes Dev. 2009;23:781–783. doi: 10.1101/gad.1787609. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 71.Veening JW, Murray H, Errington J. A mechanism for cell cycle regulation of sporulation initiation in Bacillus subtilis . Genes Dev. 2009;23:1959–1970. doi: 10.1101/gad.528209. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72.Walsh C, Wright G. Introduction: antibiotic resistance. Chem Rev. 2005;105:391–394. doi: 10.1021/cr030100y. [DOI] [PubMed] [Google Scholar]
- 73.Papadopoulos D, Schneider D, Meier-Eiss J, Arber W, Lenski RE, et al. Genomic evolution during a 10,000-generation experiment with bacteria. Proc Natl Acad Sci U S A. 1999;96:3807–3812. doi: 10.1073/pnas.96.7.3807. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74.Han TH, Lee JH, Cho MH, Wood TK, Lee J. Environmental factors affecting indole production in Escherichia coli . Res Microbiol. 2011;162:108–116. doi: 10.1016/j.resmic.2010.11.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 75.Takahashi K. Influence of bacteria on epigenetic gene control. Cell Mol Life Sci. 2014;71:1045–1054. doi: 10.1007/s00018-013-1487-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 76.Katju V, Bergthorsson U. Old trade, new tricks: insights into the spontaneous mutation process from the partnering of classical mutation accumulation experiments with high-throughput genomic approaches. Genome Biol Evol. 2019;11:136–165. doi: 10.1093/gbe/evy252. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 77.Heilbron K, Toll-Riera M, Kojadinovic M, MacLean RC. Fitness is strongly influenced by rare mutations of large effect in a microbial mutation accumulation experiment. Genetics. 2014;197:981–990. doi: 10.1534/genetics.114.163147. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 78.Halligan DL, Keightley PD. Spontaneous mutation accumulation studies in evolutionary genetics. Annu Rev Ecol Evol Syst. 2009;40:151–172. doi: 10.1146/annurev.ecolsys.39.110707.173437. [DOI] [Google Scholar]
- 79.Mohammad B. HN, Pezeshki P. Bacterial mutation; types, mechanisms and mutant detection methods: a review. Eur Sci J. 2013 [Google Scholar]
- 80.Roth JR, Benson N, Galitski T, Haack K, Lawrence JG, et al. Rearrangements of the bacterial chromosome: formation and applications. Escherichia coli and Salmonella: Cell Mol Biol. 1996;2:2256–2276. [Google Scholar]
- 81.Sun S, Ke R, Hughes D, Nilsson M, Andersson DI, et al. Genome-wide detection of spontaneous chromosomal rearrangements in bacteria. PLoS One. 2012;7:e42639. doi: 10.1371/journal.pone.0042639. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 82.Cao S, Brandis G, Huseby DL, Hughes D. Positive selection during niche adaptation results in large-scale and irreversible rearrangement of chromosomal gene order in bacteria. Mol Biol Evol. 2022;39:msac069. doi: 10.1093/molbev/msac069. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 83.Watford S, Steven J W. StatPearls. 2021. Bacterial DNA mutations. [Google Scholar]
- 84.Maughan H, Masel J, Birky CW, Jr, Nicholson WL. The roles of mutation accumulation and selection in loss of sporulation in experimental populations of Bacillus subtilis . Genetics. 2007;177:937–948. doi: 10.1534/genetics.107.075663. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 85.Barreto HC, Cordeiro TN, Henriques AO, Gordo I. Rampant loss of social traits during domestication of a Bacillus subtilis natural isolate. Sci Rep. 2020;10:1–16. doi: 10.1038/s41598-020-76017-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 86.Maughan H, Callicotte V, Hancock A, Birky CW, Jr, Nicholson WL, et al. The population genetics of phenotypic deterioration in experimental populations of Bacillus subtilis . Evolution. 2006;60:686–695. doi: 10.1111/j.0014-3820.2006.tb01148.x. [DOI] [PubMed] [Google Scholar]
- 87.Siranosian KJ, Grossman AD. Activation of spo0A transcription by sigma H is necessary for sporulation but not for competence in Bacillus subtilis . J Bacteriol. 1994;176:3812–3815. doi: 10.1128/jb.176.12.3812-3815.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 88.Siebring J, Elema MJH, Drubi Vega F, Kovács AT, Haccou P, et al. Repeated triggering of sporulation in Bacillus subtilis selects against a protein that affects the timing of cell division. ISME J. 2014;8:77–87. doi: 10.1038/ismej.2013.128. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 89.Grossman AD. Genetic networks controlling the initiation of sporulation and the development of genetic competence in Bacillus subtilis . Annu Rev Genet. 1995;29:477–508. doi: 10.1146/annurev.ge.29.120195.002401. [DOI] [PubMed] [Google Scholar]
- 90.Carvalho ALU de, Oliveira FHPC de, Mariano R de LR, Gouveia ER, Souto-Maior AM. Growth, sporulation and production of bioactive compounds by Bacillus subtilis R14. Braz arch biol technol. 2010;53:643–652. doi: 10.1590/S1516-89132010000300020. [DOI] [Google Scholar]
- 91.Cosby WM, Zuber P. Regulation of Bacillus subtilis sigmaH (spo0H) and AbrB in response to changes in external pH. J Bacteriol. 1997;179:6778–6787. doi: 10.1128/jb.179.21.6778-6787.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 92.Gauvry E, Mathot AG, Couvert O, Leguérinel I, Coroller L. Effects of temperature, pH and water activity on the growth and the sporulation abilities of Bacillus subtilis BSB1. Int J Food Microbiol. 2021;337:108915. doi: 10.1016/j.ijfoodmicro.2020.108915. [DOI] [PubMed] [Google Scholar]
- 93.Dempfle L. Conservation, creation, and utilization of genetic variation. JDS. 1990;73:2593–2600. doi: 10.3168/jds.S0022-0302(90)78946-1. [DOI] [Google Scholar]
- 94.Koskiniemi S, Sun S, Berg OG, Andersson DI. Selection-driven gene loss in bacteria. PLoS Genet. 2012;8:e1002787. doi: 10.1371/journal.pgen.1002787. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 95.Leitch J, Collier PJ. A new chemically-defined medium for Bacillus subtilis (168) NCIMB 12900. Lett Appl Microbiol. 1996;22:18–20. doi: 10.1111/j.1472-765X.1996.tb01099.x. [DOI] [Google Scholar]
- 96.Wood DE, Salzberg SL. Kraken: ultrafast metagenomic sequence classification using exact alignments. Genome Biol. 2014;15:1–12. doi: 10.1186/gb-2014-15-3-r46. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 97.Ondov BD, Bergman NH, Phillippy AM. Interactive metagenomic visualization in a Web browser. BMC Bioinformatics. 2011;12:1–10. doi: 10.1186/1471-2105-12-385. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 98.Dervaux J, Magniez JC, Libchaber A. On growth and form of Bacillus subtilis biofilms. Interface Focus. 2014;4:20130051. doi: 10.1098/rsfs.2013.0051. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 99.Manabe K, Kageyama Y, Tohata M, Ara K, Ozaki K, et al. High external pH enables more efficient secretion of alkaline α-amylase AmyK38 by Bacillus subtilis . Microb Cell Fact. 2012;11:1–3. doi: 10.1186/1475-2859-11-74. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 100.Romero S, Merino E, Bolívar F, Gosset G, Martinez A. Metabolic engineering of Bacillus subtilis for ethanol production: lactate dehydrogenase plays a key role in fermentative metabolism. Appl Environ Microbiol. 2007;73:5190–5198. doi: 10.1128/AEM.00625-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 101.Arnaouteli S, Bamford NC, Stanley-Wall NR, Kovács ÁT. Bacillus subtilis biofilm formation and social interactions. Nat Rev Microbiol. 2021;19:600–614. doi: 10.1038/s41579-021-00540-9. [DOI] [PubMed] [Google Scholar]
- 102.López D, Vlamakis H, Kolter R. Biofilms. Cold Spring Harb Perspect Biol. 2010;2:a000398. doi: 10.1101/cshperspect.a000398. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 103.Hu P, Suh J, Yoshikawa A, Zhu J. The effects of glucose concentration on the growth rates of wild type and PDC1 mutant Saccharomyces cerevisiae . The Expedition. 2014;4 [Google Scholar]
- 104.Duanis-Assaf D, Steinberg D, Shemesh M. Efficiency of Bacillus subtilis metabolism of sugar alcohols governs its probiotic effect against cariogenic Streptococcus mutans . Artif Cells Nanomed Biotechnol. 2020;48:1222–1230. doi: 10.1080/21691401.2020.1822855. [DOI] [PubMed] [Google Scholar]
- 105.Powers EM. Method for obtaining free bacterial spores of Bacillus subtilis var. niger. Appl Microbiol. 1968;16:180–181. doi: 10.1128/am.16.1.180-181.1968. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 106.Phillips ZEV, Strauch MA. Bacillus subtilis sporulation and stationary phase gene expression. Cell Mol Life Sci. 2002;59:392–402. doi: 10.1007/s00018-002-8431-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 107.Saujet L, Monot M, Dupuy B, Soutourina O, Martin-Verstraete I. The key sigma factor of transition phase, SigH, controls sporulation, metabolism, and virulence factor expression in Clostridium difficile . J Bacteriol. 2011;193:3186–3196. doi: 10.1128/JB.00272-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 108.Ferraris RP, Yasharpour SA, Lloyd KC, Mirzayan RA, Diamond JM. Luminal glucose concentrations in the gut under normal conditions. Am J Physiol. 1990;259:G822–37. doi: 10.1152/ajpgi.1990.259.5.G822. [DOI] [PubMed] [Google Scholar]
- 109.Stümpel F, Burcelin R, Jungermann K, Thorens B. Normal kinetics of intestinal glucose absorption in the absence of GLUT2: evidence for a transport pathway requiring glucose phosphorylation and transfer into the endoplasmic reticulum. Proc Natl Acad Sci U S A. 2001;98:11330–11335. doi: 10.1073/pnas.211357698. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 110.Knopp JL, Signal M, Harris DL, Marics G, Weston P, et al. Modelling intestinal glucose absorption in premature infants using continuous glucose monitoring data. Comput Methods Programs Biomed. 2019;171:41–51. doi: 10.1016/j.cmpb.2018.10.005. [DOI] [PubMed] [Google Scholar]
- 111.Fallingborg J. Intraluminal pH of the human gastrointestinal tract. Dan Med Bull. 1999;46:183–196. [PubMed] [Google Scholar]
- 112.Evans DF, Pye G, Bramley R, Clark AG, Dyson TJ, et al. Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut. 1988;29:1035–1041. doi: 10.1136/gut.29.8.1035. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 113.Chen L, Tuo B, Dong H. Regulation of intestinal glucose absorption by ion channels and transporters. Nutrients. 2016;8:43. doi: 10.3390/nu8010043. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 114.Pácha J. Development of intestinal transport function in mammals. Physiol Rev. 2000;80:1633–1667. doi: 10.1152/physrev.2000.80.4.1633. [DOI] [PubMed] [Google Scholar]
- 115.Cavalli C, Teng C, Battaglia FC, Bevilacqua G. Free sugar and sugar alcohol concentrations in human breast milk. J Pediatr Gastroenterol Nutr. 2006;42:215–221. doi: 10.1097/01.mpg.0000189341.38634.77. [DOI] [PubMed] [Google Scholar]
- 116.Scano P, Murgia A, Demuru M, Consonni R, Caboni P. Metabolite profiles of formula milk compared to breast milk. Food Res Int. 2016;87:76–82. doi: 10.1016/j.foodres.2016.06.024. [DOI] [PubMed] [Google Scholar]
- 117.Hove H, Nørgaard H, Mortensen PB. Lactic acid bacteria and the human gastrointestinal tract. Eur J Clin Nutr. 1999;53:339–350. doi: 10.1038/sj.ejcn.1600773. [DOI] [PubMed] [Google Scholar]
- 118.Rider AK, Schedl HP, Nokes G, Shining S. Small intestinal glucose transport. Proximal-distal kinetic gradients. J Gen Physiol. 1967;50:1173–1182. doi: 10.1085/jgp.50.5.1173. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 119.Dound YA, Jadhav SS, Devale M, Bayne T, Krishnan K, et al. The effect of probiotic Bacillus subtilis HU58 on immune function in healthy human. Indian Pract. 2017;70:15–20. [Google Scholar]
- 120.Cook AM, Lund BM. Total counts of bacterial spores using counting slides. J Gen Microbiol. 1962;29:97–104. doi: 10.1099/00221287-29-1-97. [DOI] [PubMed] [Google Scholar]
- 121.Morris S, Nicholls J. An evaluation of optical density to estimate fungal spore concentrations in water suspensions. Strain. 1978;1:1240–1242. [Google Scholar]
- 122.Galperin MY, Mekhedov SL, Puigbo P, Smirnov S, Wolf YI, et al. Genomic determinants of sporulation in Bacilli and Clostridia: towards the minimal set of sporulation-specific genes. Environ Microbiol. 2012;14:2870–2890. doi: 10.1111/j.1462-2920.2012.02841.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 123.Das G, Prasad MP. Isolation, purification & mass production of protease enzyme from Bacillus subtilis . Int Res J Microbiol. 2010;1:26–31. [Google Scholar]
- 124.Gromova LV, Fetissov SO, Gruzdkov AA. Mechanisms of glucose absorption in the small intestine in health and metabolic diseases and their role in appetite regulation. Nutrients. 2021;13:2474. doi: 10.3390/nu13072474. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 125.Sonenshein AL, Hoch JA, Losick R. Bacillus Subtilis and Its Closest Relatives. Washington, DC, USA: 2001. pp. 519–525. [DOI] [Google Scholar]
- 126.Onyenwoke RU, Brill JA, Farahi K, Wiegel J. Sporulation genes in members of the low G+C Gram-type-positive phylogenetic branch (Firmicutes) Arch Microbiol. 2004;182:182–192. doi: 10.1007/s00203-004-0696-y. [DOI] [PubMed] [Google Scholar]
- 127.Traag BA, Pugliese A, Eisen JA, Losick R. Gene conservation among endospore-forming bacteria reveals additional sporulation genes in Bacillus subtilis . J Bacteriol. 2013;195:253–260. doi: 10.1128/JB.01778-12. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 128.Govin J, Berger SL. Genome reprogramming during sporulation. Int J Dev Biol. 2009;53:425–432. doi: 10.1387/ijdb.082687jg. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 129.Keijser BJF, Ter Beek A, Rauwerda H, Schuren F, Montijn R, et al. Analysis of temporal gene expression during Bacillus subtilis spore germination and outgrowth. J Bacteriol. 2007;189:3624–3634. doi: 10.1128/JB.01736-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 130.Mutlu A, Kaspar C, Becker N, Bischofs IB. A spore quality-quantity tradeoff favors diverse sporulation strategies in Bacillus subtilis . ISME J. 2020;14:2703–2714. doi: 10.1038/s41396-020-0721-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 131.González-Pastor JE. Cannibalism: a social behavior in sporulating Bacillus subtilis . FEMS Microbiol Rev. 2011;35:415–424. doi: 10.1111/j.1574-6976.2010.00253.x. [DOI] [PubMed] [Google Scholar]
- 132.Lamsa A, Liu WT, Dorrestein PC, Pogliano K. The Bacillus subtilis cannibalism toxin SDP collapses the proton motive force and induces autolysis. Mol Microbiol. 2012;84:486–500. doi: 10.1111/j.1365-2958.2012.08038.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 133.Höfler C, Heckmann J, Fritsch A, Popp P, Gebhard S, et al. Cannibalism stress response in Bacillus subtilis . Microbiology. 2016;162:164–176. doi: 10.1099/mic.0.000176. [DOI] [PubMed] [Google Scholar]
- 134.Pérez Morales TG, Ho TD, Liu WT, Dorrestein PC, Ellermeier CD. Production of the cannibalism toxin SDP is a multistep process that requires SdpA and SdpB. J Bacteriol. 2013;195:3244–3251. doi: 10.1128/JB.00407-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 135.Figaro S, Durand S, Gilet L, Cayet N, Sachse M, et al. Bacillus subtilis mutants with knockouts of the genes encoding ribonucleases RNase Y and RNase J1 are viable, with major defects in cell morphology, sporulation, and competence. J Bacteriol. 2013;195:2340–2348. doi: 10.1128/JB.00164-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 136.Wang M, Yu H, Li X, Shen Z. Single-gene regulated non-spore-forming Bacillus subtilis: Construction, transcriptome responses, and applications for producing enzymes and surfactin. Metab Eng. 2020;62:235–248. doi: 10.1016/j.ymben.2020.08.008. [DOI] [PubMed] [Google Scholar]
- 137.Molle V, Fujita M, Jensen ST, Eichenberger P, González-Pastor JE, et al. The Spo0A regulon of Bacillus subtilis . Mol Microbiol. 2003;50:1683–1701. doi: 10.1046/j.1365-2958.2003.03818.x. [DOI] [PubMed] [Google Scholar]
- 138.Fujita M, Losick R. The master regulator for entry into sporulation in Bacillus subtilis becomes a cell-specific transcription factor after asymmetric division. Genes Dev. 2003;17:1166–1174. doi: 10.1101/gad.1078303. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 139.Shafikhani SH, Leighton T. AbrB and Spo0E control the proper timing of sporulation in Bacillus subtilis . Curr Microbiol. 2004;48:262–269. doi: 10.1007/s00284-003-4186-2. [DOI] [PubMed] [Google Scholar]
- 140.Zuber PE, Losick RI. Role of AbrB in Spo0A- and Spo0B-dependent utilization of a sporulation promoter in Bacillus subtilis . J Bacteriol. 1987;169:2223–2230. doi: 10.1128/jb.169.5.2223-2230.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.